Patient supportPatient resources

Brochures and forms

Patient enrollment form

Use this form to enroll in Spark Therapeutics Generation Patient ServicesSM (not for patients at ocular gene therapy treatment centers) and to schedule consultations.

Enrollment is not required to receive LUXTURNA treatment.

Download PDF

Patient and caregiver insurance guide

Navigate health insurance options and treatment support with this helpful guide.

Download PDF

Work/school time-off request information

Guidance on how to request time off from work or school for a medical leave of absence

Download PDF for workDownload PDF for school

Mentee brochure

Learn how the Mentor Program connects people who are considering treatment with people who have already been treated with LUXTURNA® (voretigene neparvovec-rzyl).

Download PDF

Navigating insurance and accessing financial assistance resources can be less stressful when you have people on your side. Spark® Therapeutics may be able to connect you with financial resources.

Learn more

Ocular gene therapy treatment centers

LUXTURNA is only administered at ocular gene therapy treatment centers. Spark Therapeutics has designated these select ocular gene therapy treatment centers to support patient care with a staff of healthcare professionals, including retinal specialists, nurses, and genetic counselors, who have experience treating people with inherited retinal diseases (IRDs).*

Preparing to visit an ocular gene therapy treatment center just got easier. After you enroll in Generation Patient Services support, we will work with your schedule and help coordinate your ocular gene therapy treatment center visits.

*Enrollment in Generation Patient Services is not required to receive treatment.

Learn more about LUXTURNA

Alkek Eye Center, Baylor College of Medicine Jamail Specialty Care Center

Houston, TX 77030

Bascom Palmer Eye Institute, University of Miami Health System

Miami, FL 33136

Boston Children’s Hospital

Boston, MA 02115

Children’s Hospital of Philadelphia

Philadelphia, PA 19104

Cincinnati Children’s Hospital

Cincinnati, OH 45229

Kellogg Eye Center, University of Michigan

Ann Arbor, MI 48105

Massachusetts Eye and Ear

Boston, MA 02114

OHSU Casey Eye Institute

Portland, OR 97239

Scheie Eye Institute Penn Presbyterian

Philadelphia, PA 19104

UAB Callahan Eye

Birmingham, AL 35233

University of Iowa Hospitals and Clinics

Iowa City, IA 52242

UPMC Eye Center

Pittsburgh, PA 15213

University of Rochester Medical Center, Flaum Eye Institute

Rochester, NY 14642

The Vision Center at Children’s Hospital Los Angeles

Los Angeles, CA 90027

IMPORTANT SAFETY INFORMATION FOR LUXTURNA (voretigene neparvovec-rzyl)

The following serious side effects may occur during or after the administration of LUXTURNA:

  • Eye infections, including a serious infection inside of the eye called endophthalmitis, that may lead to blindness.
  • Permanent decline in visual acuity, or the sharpness of central vision.
  • Changes in the retina (the thin layer of tissue in the back of the eye) that can lead to vision loss including:
    • development of a hole, thinning, or loss of function of the retina, separation of the layers in the center of the retina, loss of retinal cells and the choroid (the layer of blood vessels that lines the back of the eye), or bleeding in the retina.
    • breaks in or wrinkling on the surface of the retina or detachment of the retina.
  • Increased pressure inside of the eye. You should follow-up with your healthcare professional as instructed to detect and treat any increased pressure in the eye as this may cause blindness.
  • Expansion of the air bubble formed in the eye after administration of LUXTURNA. You should avoid air travel, travel to high elevations, or scuba diving until your healthcare professional has told you that the air bubble formed in the eye following administration of LUXTURNA has disappeared. Engaging in these activities while the air bubble is present can cause permanent vision loss.
  • Formation or worsening of cataract (clouding of the lens inside of the eye).

Tell your healthcare professional right away if you have any of the following symptoms of these serious side effects:

  • Seeing floaters (specks that float about in your field of vision)
  • Pain in the eye
  • Any change in vision including decreased vision or blurred vision
  • Seeing flashes of light

The following are the most common side effects that may occur with LUXTURNA:

  • Redness of the eye
  • Cataract (clouding of the lens inside of the eye)
  • Increased pressure inside of the eye
  • Breaks in the retina
  • Dellen (thinning of the clear layer in the front of the eye)
  • Development of a hole in the center of the retina
  • Subretinal deposits (deposits under the retina)
  • Eye swelling, irritation or pain
  • Wrinkling on the surface of the center of the retina

Treatment with LUXTURNA is not recommended for patients younger than 12 months of age because the retina is still growing, which may affect how LUXTURNA works.

Because small quantities of LUXTURNA may be in your tears for a short period of time, for the first 7 days after administration of LUXTURNA, place any waste material from dressings, tears and nasal secretions in sealed bags prior to disposal.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Spark® Therapeutics at 1-855-SPARKTX (1-855-772-7589).

This information does not take the place of talking to your healthcare professional about your medical condition or treatment. If you have questions about LUXTURNA after reading this information, ask your healthcare professional.

Please see the US Full Prescribing Information for LUXTURNA.

INDICATION

LUXTURNA (voretigene neparvovec-rzyl) is a prescription gene therapy product used for the treatment of patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can only be confirmed through genetic testing.

Show more

Accessibility policy

Throughout the creation of this website, we followed accessibility guidelines established by the World Wide Web Consortium (W3C®), an international group that develops website standards. Sites that don’t meet these guidelines can be challenging, or even unusable, for people with low vision. To avoid that possibility, we relied on W3C principles to guide each step, and to make this site accessible to all of our visitors.

Adjust the setting of the site for easier reading.

HIGH CONTRAST
Font size
AA
Line height